Myoclonic Status Epilepticus

Myoclonic status epilepticus is a prolonged or repetitive state of myoclonic seizure activity without full recovery between episodes. It encompasses a heterogeneous group of aetiologies with markedly differing prognosis.

These range from the generally poor prognosis acute posthypoxic form to myoclonic status in idiopathic generalised epilepsy syndromes and progressive myoclonic epilepsy syndromes. Idiopathic generalised epilepsy generally carries a favourable prognosis and good treatment response.

Accurate identification of the underlying context is essential. Management and expected outcome diverge substantially between these scenarios.

Pathophysiology and classification by context

• Idiopathic generalised epilepsy (most classically juvenile myoclonic epilepsy) reflects exacerbation or breakthrough of the underlying genetic generalised epilepsy syndrome. Identifiable triggers include sleep deprivation, alcohol and medication non adherence. Response to appropriate antiseizure medication is typically good, with a generally favourable prognosis once controlled.
• Progressive myoclonic epilepsy syndromes are a group of rare, generally genetically determined conditions, including Unverricht Lundborg disease and Lafora body disease. They are characterised by progressive myoclonus, epilepsy and, over time, cognitive decline.
• Myoclonic status in these syndromes reflects the underlying progressive neurodegenerative process. Long term prognosis is generally poor because of the relentlessly progressive nature of the condition, despite symptomatic seizure control.
• Acute symptomatic myoclonic status occurs with severe acute cerebral insult. The most classic cause is hypoxic ischaemic injury. It also occurs with severe metabolic derangement, certain toxic exposures or severe acute encephalitis.
• In acute symptomatic disease, prognosis is determined predominantly by the severity and nature of the underlying insult rather than by the myoclonic status itself.

• The picture is frequent, often continuous or near continuous, myoclonic jerking affecting the face, trunk and limbs. Consciousness is typically not impaired to the degree seen in other forms of status epilepticus. Myoclonic seizures characteristically do not impair consciousness as tonic clonic or absence status do.
• The underlying context may itself produce altered consciousness, particularly in acute symptomatic disease after severe cerebral insult. This reflects the severity of the causative brain injury rather than the myoclonic activity per se.
• Systematically establish the clinical context in every presentation. It provides essential diagnostic and prognostic information. Relevant elements are epilepsy history, precipitating factors, and features suggesting an acute severe cerebral insult or a progressive neurodegenerative process.
• Progressive myoclonic epilepsy presentations typically show a background of gradually worsening myoclonus and other seizure types over months to years before presentation with status. Evolving cognitive decline, ataxia and other neurological features reflect the specific underlying progressive condition.

• Electroencephalography is essential. It confirms the electrographic correlate of the clinical myoclonic activity and characterises the background pattern, which differs substantially and informatively between aetiological contexts.
• A generalised polyspike and wave pattern on a preserved, reactive background supports an idiopathic generalised epilepsy context. A severely abnormal, suppressed or burst suppression background supports acute severe symptomatic disease.
• Pursue full metabolic and toxicological screening to identify or exclude an acute precipitating metabolic or toxic cause. This is particularly relevant where the presentation occurs without a pre-existing epilepsy history or other clear context.
• Where a progressive myoclonic epilepsy syndrome is suspected from the clinical trajectory and associated features, specific genetic testing of the relevant candidate genes supports definitive diagnosis. It also informs prognosis and genetic counselling.
• Where indicated, skin or other tissue biopsy for histopathological evaluation is relevant to certain syndromes with characteristic tissue findings.
• Direct neuroimaging according to the clinical context. Acute symptomatic disease warrants assessment for the underlying acute structural or hypoxic ischaemic cause. In progressive myoclonic epilepsy syndromes, imaging may be non specific or, in some conditions, show characteristic progressive cerebral or cerebellar atrophy on serial assessment.

• Treat myoclonic status in idiopathic generalised epilepsy with intravenous sodium valproate or levetiracetam as first line agents. Both offer good efficacy for this syndrome and seizure type.
• Use benzodiazepines for acute, immediate seizure termination alongside starting an appropriate longer acting agent for ongoing control.
• Identify and, where possible, correct any precipitating factor (sleep deprivation, alcohol, medication non adherence). This is an important component of management alongside acute pharmacological treatment.
• Generally avoid sodium channel blocking antiseizure medications in myoclonic status in idiopathic generalised epilepsy or progressive myoclonic epilepsy syndromes. These include carbamazepine, phenytoin and lamotrigine, the latter with more variable effect depending on the syndrome. These agents can exacerbate myoclonic seizures in this population.
• This is an important point of distinction from the broader, more generic status epilepticus treatment approach for other seizure types.
• Manage acute symptomatic myoclonic status (particularly the posthypoxic form) as detailed in full under posthypoxic myoclonus. Integrate treatment into full prognostication and goals of care discussion, given the frequently poor underlying prognosis. This contrasts clearly with the generally favourable outcome of treated myoclonic status in idiopathic generalised epilepsy.
• Manage progressive myoclonic epilepsy syndromes with symptomatic antiseizure medication, again avoiding sodium channel blocking agents given the risk of myoclonus exacerbation. Levetiracetam, sodium valproate and, in some syndromes, perampanel or piracetam are used according to the syndrome and individual response.
• Provide full supportive, multidisciplinary management of the broader progressive neurological decline. No disease modifying treatment is currently available for the great majority of these genetically determined, progressive conditions.
• Genetic counselling for the family is an essential component of management where a specific progressive myoclonic epilepsy syndrome is confirmed. These conditions are generally inherited, with implications for other family members and future reproductive planning.